SCHEMBL2789560

SCHEMBL2789560

Cc1cc(Cl)n2nc(NC(=O)c3cccnc3)nc2c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.54
▸ MAP3K5 Q99683 1/20 0.52
▸ TDP2 O95551 1/20 0.48
▸ HPGD P15428 2/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ RAB9A P51151 4/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ NPC1 O15118 3/20 0.46
▸ KDM4E B2RXH2 3/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ MAPK1 P28482 2/20 0.45
▸ KCNMA1 Q12791 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ LMNA P02545 1/20 0.44
▸ HIF1A Q16665 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2788780 0.89 MAP3K5 (0.54) TDP1MAP3K5TDP2HPGDHSD17B10
SCHEMBL2785921 0.84 MAP3K5 (0.70) MAP3K5TDP2HPGDHSD17B10ALOX15
SCHEMBL2773629 0.84 TDP2 (0.52) MAP3K5TDP2HPGDHSD17B10ALOX15
SCHEMBL2790924 0.83 MAP3K5 (0.54) TDP1MAP3K5TDP2HPGDHSD17B10
SCHEMBL2789550 0.80 MAP3K5 (0.51) TDP1MAP3K5HPGDHSD17B10ALOX15
SCHEMBL2790048 0.78 MAP3K5 (0.53) TDP1MAP3K5TDP2HPGDHSD17B10
SCHEMBL2789556 0.76 HSD17B10 (0.56) TDP1MAP3K5HPGDHSD17B10ALOX15
SCHEMBL2807203 0.75 MAP3K5 (0.75) MAP3K5TDP2HPGDHSD17B10ALOX15
SCHEMBL2771699 0.75 MAP3K5 (0.50) MAP3K5TDP2HPGDHSD17B10ALOX15
SCHEMBL12317224 0.75 MAP3K5 (0.47) TDP1MAP3K5TDP2HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120238565-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS MERCK SERONO SA (CH) 2012-09-20 — — US claimed
US-20100197681-A1 Triazolopyridine Compounds and Their Use as Ask Inhibitors MERCK SERONO SA (CH) 2010-08-05 — — US claimed
US-20100197679-A1 COMPOUNDS GLAXO GROUP LIMITED 2010-08-05 — — US claimed
EP-2181112-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS Merck Serono S.A. (CH) 2010-05-05 — — EP claimed
WO-2009027283-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS MERCK SERONO S.A. (CH) 2009-03-05 — — WO claimed
US-20120238565-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS MERCK SERONO SA (CH) 2012-09-20 — — US disclosed
US-20120238565-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS MERCK SERONO SA (CH) 2012-09-20 — — US disclosed
US-8263595-B2 Triazolopyridine compounds and their use as ask inhibitors MERCK SERONO SA (CH) 2012-09-11 — — US disclosed
US-8263595-B2 Triazolopyridine compounds and their use as ask inhibitors MERCK SERONO SA (CH) 2012-09-11 — — US disclosed
US-20100197681-A1 Triazolopyridine Compounds and Their Use as Ask Inhibitors MERCK SERONO SA (CH) 2010-08-05 — — US disclosed
US-20100197681-A1 Triazolopyridine Compounds and Their Use as Ask Inhibitors MERCK SERONO SA (CH) 2010-08-05 — — US disclosed
EP-2181112-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS Merck Serono S.A. (CH) 2010-05-05 — — EP disclosed
WO-2009027283-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS MERCK SERONO S.A. (CH) 2009-03-05 — — WO disclosed
WO-2009027283-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS MERCK SERONO S.A. (CH) 2009-03-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197679-A1 COMPOUNDS NRDC, MRPL21, NISCH TDP1 4367/4885MAP3K5 3451/4885TDP2 4390/4885
US-20100197681-A1 Triazolopyridine Compounds and Their Use as Ask Inhibitors MAP3K5, MAPKAPK5, MAP3K9 TDP1 38/4885MAP3K5 1/4885TDP2 57/4885
US-20120238565-A1 TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS MAP3K5, MAPKAPK5, MAP3K9 TDP1 38/4885MAP3K5 1/4885TDP2 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback